Kausik Ray, MD, FMedSci

Articles by Kausik Ray, MD, FMedSci

Closing Thoughts on ASCVD Management

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 12th 2026

Experts reveal how risk assessment, LDL-C targets, and smarter follow-up boost adherence—turning guidelines into real cardiovascular prevention.

Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Learn how clinicians reach ultra-low LDL targets in high-risk patients using ezetimibe, PCSK9s, and smarter insurance documentation.

Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Why patients quit cholesterol therapy—and how LDL checkups, reminders, and longer-acting injectables improve lifelong medication adherence.

Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statins, ezetimibe, bempedoic acid and PCSK9 inhibitors for side effects, dosing preferences, and shared decision-making tips.

Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statin side effects with ezetimibe, bempedoic acid and PCSK9 inhibitors, plus practical dosing tips and shared decision-making.

Advancing ASCVD Management with PCSK9 Inhibitors

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

Explore where ezetimibe and bempedoic acid fit for statin‑reluctant patients, lowering LDL with proven outcomes and diabetes benefits.

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

See how coronary calcium images and risk graphs boost engagement, drive LDL-lowering choices, and help more patients reach cholesterol goals.

Driving Patient Engagement in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

Navigating Combination Therapy and Access Challenges in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Learn how clinicians personalize LDL-lowering therapy, address statin fears, and choose pills or injections to hit cholesterol goals despite cost barriers.

Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Clinicians shift from “hyper” labels to atherosclerosis risk, using diabetes markers and LDL targets to prevent heart attack and stroke.

Examining the 2026 ACC/AHA Dyslipidemia Guidelines for ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 1st 2026

ASCVD Risk Assessment and LDL-C Management

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 1st 2026

Kausik Ray, MD, FMedSci

Articles by Kausik Ray, MD, FMedSci

Closing Thoughts on ASCVD Management

Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD

Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD

Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

Advancing ASCVD Management with PCSK9 Inhibitors

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

Driving Patient Engagement in ASCVD

Navigating Combination Therapy and Access Challenges in ASCVD

Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

Examining the 2026 ACC/AHA Dyslipidemia Guidelines for ASCVD

ASCVD Risk Assessment and LDL-C Management

Latest Updated Articles

Trending on HCPLive

Diagnostic Pearls and New Therapies in Connective Tissue Disease, With Michelle Min, MD

Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm

VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities

Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM

CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D